MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative (“Asia PGI”) have recently announced collaboration aimed at enhancing pathogen genomics sequencing efforts across Asia. This collaboration underscores a shared commitment to supporting public health initiatives through advanced life science technology.

Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device) in Japan.

GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study.

Illumina and Macrogen announced on Monday that they are collaborating to sequence and analyze 145,952 genomes as part of South Korea's National Bio Big Data project.

Hong Kong-based genomic testing firm Prenetics on Wednesday announced that its Q3 revenues rose 59 percent year over year.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector. The agreement offers select customers the opportunity to access Tagomics’ and Agilent Technologies’ combined innovative offerings through an exclusive technology access program hosted out of Tagomics’ service lab in Cambridge.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2024 and updated full-year guidance.